TEANECK, N.J., Jan. 25, 2016 -- Phibro Animal Health Corporation (“Phibro”) (NASDAQ:PAHC) today announced it has completed its purchase of the assets of MVP Laboratories, Inc. (“MVP”), a developer, manufacturer and marketer of livestock vaccines, vaccine adjuvants and other products based in Omaha, Nebraska. Phibro previously announced an agreement to purchase the assets of MVP Laboratories, Inc. on January 12, 2016.
About Phibro Animal Health Corporation
Phibro Animal Health Corporation is a diversified global developer, manufacturer and marketer of a broad range of animal health and mineral nutrition products for use in the production of poultry, swine, cattle, dairy and aquaculture. The company reported net sales of $749 million for the fiscal year ended June 30, 2015. For further information, please visit www.pahc.com.
Forward-Looking Statements
This communication contains forward-looking statements, which reflect Phibro’s current views with respect to business plans or prospects, the transactions described herein, and other future events. You can identify forward-looking statements by the fact that they do not relate strictly to historical or current facts. These statements may include words such as “aim,” “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “outlook,” “potential,” “project,” “projection,” “plan,” “intend,” “seek,” “believe,” “may,” “could,” “would,” “will,” “should,” “can,” “can have,” “likely,” the negatives thereof and other words and terms of similar meaning in connection with any discussion of the timing or nature of future operating or financial performance or other events. These statements are not guarantees of future performance or actions. Forward-looking statements are subject to risks and uncertainties. If one or more of these risks or uncertainties materialize, or if management’s underlying assumptions prove to be incorrect, actual results may differ materially from those contemplated by a forward-looking statement. Forward-looking statements speak only as of the date on which they are made. Phibro expressly disclaims any obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise. A further list and description of risks, uncertainties and other matters can be found in our Annual Report on Form 10-K and our Quarterly Reports on Form 10-Q, including in the sections thereof captioned “Forward-Looking Statements” and “Risk Factors.” These filings and subsequent filings are available online at www.sec.gov, www.pahc.com, or on request from Phibro.
Contact Phibro Animal Health Corporation Richard Johnson Chief Financial Officer +1-201-329-7300 [email protected]


LG Energy Solution Shares Slide After Ford Cancels EV Battery Supply Deal
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand
Instacart Stock Drops After FTC Probes AI-Based Price Discrimination Claims
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery
Shell M&A Chief Exits After BP Takeover Proposal Rejected
Union-Aligned Investors Question Amazon, Walmart and Alphabet on Trump Immigration Policies
Robinhood Expands Sports Event Contracts With Player Performance Wagers
Trump Administration Reviews Nvidia H200 Chip Sales to China, Marking Major Shift in U.S. AI Export Policy
FedEx Beats Q2 Earnings Expectations, Raises Full-Year Outlook Despite Stock Dip
Volaris and Viva Agree to Merge, Creating Mexico’s Largest Low-Cost Airline Group
MetaX IPO Soars as China’s AI Chip Stocks Ignite Investor Frenzy
Treasury Wine Estates Shares Plunge on Earnings Warning Amid U.S. and China Weakness
ANZ New CEO Forgoes Bonus After Shareholders Reject Executive Pay Report
Sanofi’s Efdoralprin Alfa Gains EMA Orphan Status for Rare Lung Disease
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns
Toyota to Sell U.S.-Made Camry, Highlander, and Tundra in Japan From 2026 to Ease Trade Tensions 



